Inovio Pharmaceuticals Inc (INO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH4623D
- Pages: 83
- October 2018
- Total Views:1289
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing a portfolio of DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. It is advancing a preclinical and clinical stage product pipeline to fight cancers of the cervix, prostate, breast, bladder, head and neck, lung, and pancreas; and to protect against and eliminate infectious diseases such as HIV, hepatitis, Ebola, Zika virus and Middle East respiratory syndrome (MERS). Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
Inovio Pharmaceuticals Inc (INO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13
Partnerships 14
Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14
Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15
Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16
Inovio Pharma Enters into Agreement with Genentech 17
Inovio Pharma and Regeneron Pharma Enter into Agreement 18
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19
Inovio Pharma Enters into Research Agreement with Wistar Institute 20
GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21
Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22
Inovio Pharma Amends Agreement with GeneOne 23
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24
Licensing Agreements 25
MedImmune Enters into Licensing Agreement with Inovio Pharma 25
Equity Offering 26
Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26
Inovio Pharma Raises USD75 Million in Public Offering of Shares 27
Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29
Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30
Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31
Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33
Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34
Inovio Pharmaceuticals Inc-Key Competitors 36
Inovio Pharmaceuticals Inc-Key Employees 37
Inovio Pharmaceuticals Inc-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 07, 2018: Inovio Pharmaceuticals reports 2018 second quarter financial results 40
May 09, 2018: Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results 42
Mar 14, 2018: Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results 44
Nov 08, 2017: Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results 47
Aug 08, 2017: Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results 50
May 10, 2017: Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results 53
Mar 15, 2017: Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results 55
Corporate Communications 58
May 24, 2018: Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D 58
Dec 11, 2017: Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development 59
Dec 06, 2017: Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors 60
Jun 28, 2017: Inovio Announces Leadership Appointments 61
Mar 21, 2017: George Bickerstaff Elected to Inovio's Board of Directors 62
Government and Public Interest 63
Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 63
Jan 18, 2018: The Wistar Institute Awarded More Than USD 1.4 Million to Create a Malaria Vaccine Through Synthetic DNA-Based Technology 64
Product News 65
Oct 08, 2018: Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies 65
Sep 21, 2017: Inovio dMAb Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies 67
09/18/2017: Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection 69
Jul 06, 2017: Inovio's DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation 70
Feb 27, 2017: Inovio's SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy 72
Clinical Trials 74
May 21, 2018: Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV-The No. 1 Sexually Transmitted Disease 74
Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy 75
Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study 77
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 78
Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers 80
Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300 81
Other Significant Developments 82
Jan 22, 2018: Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models 82
Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83
List Of Figure
List of Figures
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inovio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13
Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14
Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15
Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16
Inovio Pharma Enters into Agreement with Genentech 17
Inovio Pharma and Regeneron Pharma Enter into Agreement 18
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19
Inovio Pharma Enters into Research Agreement with Wistar Institute 20
GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21
Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22
Inovio Pharma Amends Agreement with GeneOne 23
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24
MedImmune Enters into Licensing Agreement with Inovio Pharma 25
Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26
Inovio Pharma Raises USD75 Million in Public Offering of Shares 27
Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29
Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30
Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31
Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33
Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34
Inovio Pharmaceuticals Inc, Key Competitors 36
Inovio Pharmaceuticals Inc, Key Employees 37
Inovio Pharmaceuticals Inc, Subsidiaries 39
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Inovio Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing a portfolio of DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. It is advancing a preclinical and clinical stage product pipeline to fight cancers of the cervix, prostate, breast, bladder, head and neck, lung, and pancreas; and to protect against and eliminate infectious diseases such as HIV, hepatitis, Ebola, Zika virus and Middle East respiratory syndrome (MERS). Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
Inovio Pharmaceuticals Inc (INO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13
Partnerships 14
Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14
Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15
Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16
Inovio Pharma Enters into Agreement with Genentech 17
Inovio Pharma and Regeneron Pharma Enter into Agreement 18
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19
Inovio Pharma Enters into Research Agreement with Wistar Institute 20
GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21
Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22
Inovio Pharma Amends Agreement with GeneOne 23
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24
Licensing Agreements 25
MedImmune Enters into Licensing Agreement with Inovio Pharma 25
Equity Offering 26
Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26
Inovio Pharma Raises USD75 Million in Public Offering of Shares 27
Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29
Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30
Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31
Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33
Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34
Inovio Pharmaceuticals Inc-Key Competitors 36
Inovio Pharmaceuticals Inc-Key Employees 37
Inovio Pharmaceuticals Inc-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Aug 07, 2018: Inovio Pharmaceuticals reports 2018 second quarter financial results 40
May 09, 2018: Inovio Pharmaceuticals Reports 2018 First Quarter Financial Results 42
Mar 14, 2018: Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results 44
Nov 08, 2017: Inovio Pharmaceuticals Reports 2017 Third Quarter Financial Results 47
Aug 08, 2017: Inovio Pharmaceuticals Reports 2017 Second Quarter Financial Results 50
May 10, 2017: Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results 53
Mar 15, 2017: Inovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results 55
Corporate Communications 58
May 24, 2018: Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D 58
Dec 11, 2017: Inovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development 59
Dec 06, 2017: Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors 60
Jun 28, 2017: Inovio Announces Leadership Appointments 61
Mar 21, 2017: George Bickerstaff Elected to Inovio's Board of Directors 62
Government and Public Interest 63
Feb 12, 2018: Inovio and The Wistar Institute Receive More Than USD 4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 63
Jan 18, 2018: The Wistar Institute Awarded More Than USD 1.4 Million to Create a Malaria Vaccine Through Synthetic DNA-Based Technology 64
Product News 65
Oct 08, 2018: Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies 65
Sep 21, 2017: Inovio dMAb Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies 67
09/18/2017: Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection 69
Jul 06, 2017: Inovio's DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation 70
Feb 27, 2017: Inovio's SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy 72
Clinical Trials 74
May 21, 2018: Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV-The No. 1 Sexually Transmitted Disease 74
Nov 29, 2017: Inovio's Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy 75
Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study 77
Jun 08, 2017: Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 78
Apr 24, 2017: Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers 80
Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300 81
Other Significant Developments 82
Jan 22, 2018: Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models 82
Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83
List Of Figure
List of Figures
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Inovio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Inovio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Inovio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Inovio Pharma Acquires DNA Therapies For Alzheimer's Disease And Multiple Sclerosis From Fudan University 13
Inovio Pharma Enters into Partnership with AIDS Malignancy Consortium 14
Inovio Pharma Enters into Partnership with Coalition for Epidemic Preparedness Innovations 15
Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 16
Inovio Pharma Enters into Agreement with Genentech 17
Inovio Pharma and Regeneron Pharma Enter into Agreement 18
Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 19
Inovio Pharma Enters into Research Agreement with Wistar Institute 20
GeneOne Life Science Enters into Research Agreement with Inovio Pharma 21
Inovio Pharma Enters into Co-Development Agreement with GeneOne Life Science 22
Inovio Pharma Amends Agreement with GeneOne 23
Path Malaria Vaccine Initiative And Inovio Pharma Partner To Accelerate Malaria Vaccine Development And Delivery Technologies 24
MedImmune Enters into Licensing Agreement with Inovio Pharma 25
Inovio Pharma Plans to Raise up to USD250 Million in Public Offering of Shares 26
Inovio Pharma Raises USD75 Million in Public Offering of Shares 27
Inovio Pharma to Raise up to USD35 Million in Private Placement of Shares 29
Inovio Pharma Raises USD6.3 Million in Public Offering of Shares 30
Inovio Pharma Raises USD87.4 Million Public Offering of Shares 31
Inovio Pharma Completes Public Offering Of Shares For USD 63.3 Million 33
Inovio Pharma Completes Public Offering Of Common Stock And Warrants For USD 15 Million 34
Inovio Pharmaceuticals Inc, Key Competitors 36
Inovio Pharmaceuticals Inc, Key Employees 37
Inovio Pharmaceuticals Inc, Subsidiaries 39
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Inovio Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 9015378249
Related Reports
Page 69 | 
May 2022
Page 76 | April 2022
Page 68 | March 2022
Page 78 | March 2022
Page 56 | October 2021